<DOC>
	<DOCNO>NCT01266902</DOCNO>
	<brief_summary>The purpose study provide continue access TMC278 HIV-1 infect patient randomize treated TMC278 Phase IIb Phase III trial .</brief_summary>
	<brief_title>A Trial With TMC278-TIDP6-C222 Continued TMC278 Access Patients Infected With Human Immunodeficiency Virus-1</brief_title>
	<detailed_description>This Phase III , open-label ( people know identity drug ) , multicenter , roll-over trial provide continue access TMC278 HIV-1 infect patient randomize ( study drug assign chance ) treat TMC278 Phase IIb ( TMC278-C204 [ C204 ] ) Phase III trial ( i.e. , TMC278-TiDP6-C209 [ C209 ] TMC278-TiDP6-C215 [ C215 ] ) continue benefit antiretroviral treatment , accord investigator . In addition , information long-term safety tolerability , include resistance data case virologic failure , oral dos TMC278 25 mg daily ( q.d . ) combination background regimen contain 2 N ( ) RTIs collect . Available efficacy data also collect . Approximately 750 HIV-1 infected individual expect participate trial . The duration participation study individual participant 2 3 year . The final/withdrawal visit Phase IIb Phase III trial first visit trial . Safety tolerability evaluate throughout trial . Visits assessment perform base local , generally accept standard care , visit occur least every 6 month . Oral tablet TMC278 25 mg daily ( q.d . ) administer together meal .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Patients HIV1 infect previously randomize receive TMC278 TMC278 clinical trial complete protocoldefined treatment period . Patients continue benefit treatment TMC278 opinion investigator . Patient comply current protocol requirement . The patient 's general medical condition , investigator 's opinion , interfere participation trial . Use disallow concomitant therapy . Females childbearing potential pregnant , without use effective birth control method , willing continue practice birth control method trial least 1 month end trial ( last intake TMC278 ) . Nonvasectomized heterosexually active male patient without use effective birth control method willing continue practice birth control method trial least 1 month end trial ( last intake TMC278 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV-1 Infection</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>TMC278-TiDP6-C222</keyword>
	<keyword>TMC278-C222</keyword>
	<keyword>TMC278</keyword>
	<keyword>Rilpivirine</keyword>
</DOC>